Understanding the Potential Impact of Different Drug Properties On SARS-CoV-2 Transmission and Disease Burden: A Modelling Analysis.
Charles WhittakerOliver John WatsonCarlos Alvarez-MorenoNasikarn AngkasekwinaiAdhiratha BoonyasiriLuis Carlos TrianaDuncan ChandaLantharita CharoenpongMethee ChayakulkeereeGraham S CookeJulio CrodaZulma M CucunubáBimandra A DjaafaraCassia F EstofoleteMaria-Eugenia GrilletNuno R FariaSilvia Figueiredo CostaDavid A Forero-PeñaDiana M GibbAnthony C GordonRaph L HamersArran HamletVera IrawanyAnupop JitmuangNukool KeurueangkulTeresia Njoki KimaniMargarita LampoAnna S LevinGustavo LopardoRima MustafaShevanthi NayagamThundon NgamprasertchaiNg'ang'a Irene Hannah NjeriMauricio L NogueiraEsteban Ortiz-PradoMauricio W PerroudAndrew N PhillipsPanuwat PromsinAmbar QaviAlison J RodgerEster C SabinoSorawat SangkaewDjayanti SariRujipas SirijatuphatAndrei C SpositoPratthana SrisangthongHayley A ThompsonZarir UdwadiaSandra Valderrama-BeltránPeter WinskillAzra C GhaniPatrick G T WalkerTimothy B HallettPublished in: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2021)
Advances in the treatment of COVID-19 to date have been focussed on hospitalised-patients and predicated on an assumption of adequate access to supportive care. Therapeutics delivered earlier in the course of infection that reduce the need for healthcare or reduce infectiousness could have significant impact, and research into their efficacy and means of delivery should be a priority.
Keyphrases
- sars cov
- healthcare
- end stage renal disease
- coronavirus disease
- ejection fraction
- chronic kidney disease
- newly diagnosed
- respiratory syndrome coronavirus
- palliative care
- prognostic factors
- small molecule
- emergency department
- quality improvement
- risk factors
- climate change
- social media
- patient reported outcomes
- chronic pain
- health information
- community acquired pneumonia